AR118235A1 - Heterociclos pentacíclicos - Google Patents
Heterociclos pentacíclicosInfo
- Publication number
- AR118235A1 AR118235A1 ARP200100583A ARP200100583A AR118235A1 AR 118235 A1 AR118235 A1 AR 118235A1 AR P200100583 A ARP200100583 A AR P200100583A AR P200100583 A ARP200100583 A AR P200100583A AR 118235 A1 AR118235 A1 AR 118235A1
- Authority
- AR
- Argentina
- Prior art keywords
- dione
- formula
- diazepin
- pyrimido
- cyclopenta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Compuesto caracterizado porque es seleccionado del grupo constituido por (3aS,14aR)-5-metil-3,3a,5,6-tetrahidro-1H-benzofuro[3,2:4,5]pirimido[1,2-a]ciclopenta[f][1,4]diazepin-4,13(2H,14aH)-diona: fórmula (1), (+)-7,7,12-trimetil-1,2,3,6,7,10,11,12,13,15b-decahidropirido[4,3:4,5]tieno[2,3:4,5]pirimido[1,2-a]pirrolo[2,1-c][1,4]diazepin-5,9-diona: fórmula (2), (3aS,14aR)-10-fluoro-5-metil-3,3a,5,6-tetrahidro-1H-benzofuro[3,2:4,5]pirimido[1,2-a]ciclopenta[f][1,4]diazepin-4,13(2H,14aH)-diona: fórmula (3), (3aS,14aR)-5,8,10-trimetil-3,3a,5,6-tetrahidro-1H-ciclopenta[f]pirido[3,2:4,5]furo[3,2:4,5]pirimido[1,2-a][1,4]diazepin-4,13(2H,14aH)-diona: fórmula (4), (3aR,14aR)-10-fluoro-5-metil-3,3a,5,6-tetrahidro-1H-benzofuro[3,2:4,5]pirimido[1,2-a]ciclopenta[f][1,4]diazepin-4,13(2H,14aH)-diona: fórmula (5), (3aR,14aR)-5-metil-10-(trifluorometil)-3,3a,5,6-tetrahidro-1H-benzofuro[3,2:4,5]pirimido[1,2-a]ciclopenta[f][1,4]diazepin-4,13(2H,14aH)-diona: fórmula (6), (3aS,14aR)-10-(2,2-difluoroetil)-5-metil-2,3,3a,5,6,9,10,11,12,14a-decahidro-1H-ciclopenta[f]pirido[4,3:4,5]tieno[2,3:4,5]pirimido[1,2-a][1,4]diazepin-4,13-diona: fórmula (7), (3aS,14aR)-10-(2-metoxietil)-5-metil-2,3,3a,5,6,9,10,11,12,14a-decahidro-1H-ciclopenta[f]pirido[4,3:4,5]tieno[2,3:4,5]pirimido[1,2-a][1,4]diazepin-4,13-diona: fórmula (8), (3aS,14aR)-10-(difluorometil)-5-metil-3,3a,5,6-tetrahidro-1H-benzofuro[3,2:4,5]pirimido[1,2-a]ciclopenta[f][1,4]diazepin-4,13(2H,14aH)-diona: fórmula (9), (2R,15bR)-2-fluoro-7,7,12-trimetil-1,2,3,6,7,10,11,12,13,15b-decahidro-5H,9H-pirido[4,3:4,5]tieno[2,3:4,5]pirimido[1,2-a]pirrolo[2,1-c][1,4]diazepin-5,9-diona: fórmula (10), (+)-(3a,14a-cis)-5,10-dimetil-1,3,3a,5,6,9,10,11,12,14a-decahidrofuro[3,4-f]pirido[4,3:4,5]tieno[2,3:4,5]pirimido[1,2-a][1,4]diazepin-4,13-diona: fórmula (11), (3aS,14aS)-5-metil-10-(trifluorometil)-2,3,3a,5,6,14a-hexahidro-1H-benzofuro[3,2:4,5]pirimido[1,2-a]ciclopenta[f][1,4]diazepin-4,13-diona: fórmula (12), (-)-12-(2-metoxietil)-7,7-dimetil-1,2,3,6,7,10,11,12,13,15b-decahidro-5H,9H-pirido[4,3:4,5]tieno[2,3:4,5]pirimido[1,2-a]pirrolo[2,1-c][1,4]diazepin-5,9-diona: fórmula (13), (3aR,14aR)-5,9-dimetil-2,3,3a,5,6,8,9,10,11,14a-decahidro-1H-ciclopenta[f]pirido[3,4:4,5]tieno[3,2:4,5]pirimido[1,2-a][1,4]diazepin-4,13-diona: fórmula (14), (3aR,10R,14aR)-10-fluoro-2,5-dimetil-2,3,3a,5,6,9,10,11,12,14a-decahidro-1H-benzo[4,5]tieno[2,3:4,5]pirimido[1,2-a]pirrolo[3,4-f][1,4]diazepin-4,13-diona: fórmula (15), (3aS,14aS)-10-(2-metoxietil)-5-metil-2,3,3a,5,6,9,10,11,12,14a-decahidro-1H-ciclopenta[f]pirido[4,3:4,5]tieno[2,3:4,5]pirimido[1,2-a][1,4]diazepin-4,13-diona: fórmula (16), y (-)-(3a,14a-trans)-2-(2-fluoroetil)-5-metil-2,3,3a,5,6,14a-hexahidro-1H-benzofuro[3,2:4,5]pirimido[1,2-a]pirrolo[3,4-f][1,4]diazepin-4,13-diona: fórmula (17), o una sal farmacéuticamente aceptable de la misma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019039351 | 2019-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118235A1 true AR118235A1 (es) | 2021-09-22 |
Family
ID=72336168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200100583A AR118235A1 (es) | 2019-03-05 | 2020-03-03 | Heterociclos pentacíclicos |
Country Status (21)
Country | Link |
---|---|
US (1) | US11358972B2 (es) |
EP (1) | EP3936190A4 (es) |
JP (1) | JP7504864B2 (es) |
KR (1) | KR20210135224A (es) |
CN (1) | CN113453762B (es) |
AR (1) | AR118235A1 (es) |
AU (1) | AU2020232044A1 (es) |
BR (1) | BR112021015975A2 (es) |
CA (1) | CA3129861A1 (es) |
CL (1) | CL2021002144A1 (es) |
CO (1) | CO2021010512A2 (es) |
EA (1) | EA202191966A1 (es) |
IL (1) | IL285511B2 (es) |
JO (1) | JOP20210219A1 (es) |
MA (1) | MA55221A (es) |
MX (1) | MX2021009685A (es) |
PE (1) | PE20211978A1 (es) |
SG (1) | SG11202108780PA (es) |
TW (1) | TWI821537B (es) |
WO (1) | WO2020179780A1 (es) |
ZA (1) | ZA202105729B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020233452A1 (en) | 2019-03-05 | 2021-09-02 | Eisai R&D Management Co., Ltd. | Salt of pentacyclic compound and crystals thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE258234C (es) | ||||
US4187306A (en) | 1977-07-26 | 1980-02-05 | Bayer Aktiengesellschaft | Benzodiazepine-diones, a process for their production and their use as medicaments |
RU2117670C1 (ru) | 1988-10-31 | 1998-08-20 | Эйсай Ко., Лтд. | Производные триазоло[1,4]диазепина и способы их получения |
TW197442B (es) | 1990-02-08 | 1993-01-01 | Pfizer | |
US5621100A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
US5756494A (en) | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
US5736992A (en) * | 1994-10-31 | 1998-04-07 | Hewlett-Packard | Pressure regulated free-ink ink-jet pen |
KR100203456B1 (ko) * | 1995-06-20 | 1999-06-15 | 한승수 | 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제 |
CL2004000348A1 (es) | 1997-04-15 | 2005-01-14 | Cephalon Inc & Kyowa Hakko Kog | Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales. |
CL2004000352A1 (es) | 1998-05-26 | 2005-05-27 | Cephalon Inc & Kyowa Hakko Kog | Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales. |
FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
DE10246207B4 (de) * | 2002-10-04 | 2008-04-03 | Disetronic Licensing Ag | Mikrodialysesonde mit spiralförmiger Leitung |
US8252520B2 (en) | 2002-10-11 | 2012-08-28 | Taivex Therapeutics Corporation | Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases |
GB0308333D0 (en) * | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
EP1807432A1 (en) | 2004-10-20 | 2007-07-18 | F. Hoffmann-Roche AG | Halogen substituted benzodiazepine derivatives |
JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
GB201100181D0 (en) * | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
WO2015174534A1 (ja) * | 2014-05-16 | 2015-11-19 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
JOP20200030A1 (ar) | 2017-09-07 | 2020-02-12 | Eisai R&D Man Co Ltd | مركب خماسي الحلقة |
AU2020233452A1 (en) | 2019-03-05 | 2021-09-02 | Eisai R&D Management Co., Ltd. | Salt of pentacyclic compound and crystals thereof |
-
2020
- 2020-03-03 EA EA202191966A patent/EA202191966A1/ru unknown
- 2020-03-03 MX MX2021009685A patent/MX2021009685A/es unknown
- 2020-03-03 PE PE2021001331A patent/PE20211978A1/es unknown
- 2020-03-03 BR BR112021015975-4A patent/BR112021015975A2/pt unknown
- 2020-03-03 CN CN202080014008.7A patent/CN113453762B/zh active Active
- 2020-03-03 WO PCT/JP2020/008881 patent/WO2020179780A1/ja active Application Filing
- 2020-03-03 AU AU2020232044A patent/AU2020232044A1/en active Pending
- 2020-03-03 CA CA3129861A patent/CA3129861A1/en active Pending
- 2020-03-03 AR ARP200100583A patent/AR118235A1/es unknown
- 2020-03-03 TW TW109106904A patent/TWI821537B/zh active
- 2020-03-03 US US16/807,335 patent/US11358972B2/en active Active
- 2020-03-03 MA MA055221A patent/MA55221A/fr unknown
- 2020-03-03 EP EP20766918.5A patent/EP3936190A4/en active Pending
- 2020-03-03 JO JOP/2021/0219A patent/JOP20210219A1/ar unknown
- 2020-03-03 KR KR1020217025605A patent/KR20210135224A/ko active Search and Examination
- 2020-03-03 IL IL285511A patent/IL285511B2/en unknown
- 2020-03-03 JP JP2021504107A patent/JP7504864B2/ja active Active
- 2020-03-03 SG SG11202108780PA patent/SG11202108780PA/en unknown
-
2021
- 2021-08-12 ZA ZA2021/05729A patent/ZA202105729B/en unknown
- 2021-08-12 CL CL2021002144A patent/CL2021002144A1/es unknown
- 2021-08-12 CO CONC2021/0010512A patent/CO2021010512A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3129861A1 (en) | 2020-09-10 |
JP7504864B2 (ja) | 2024-06-24 |
CO2021010512A2 (es) | 2021-10-29 |
US20200283452A1 (en) | 2020-09-10 |
ZA202105729B (en) | 2022-08-31 |
MX2021009685A (es) | 2021-09-10 |
US11358972B2 (en) | 2022-06-14 |
PE20211978A1 (es) | 2021-10-05 |
JPWO2020179780A1 (es) | 2020-09-10 |
EP3936190A4 (en) | 2022-11-16 |
TW202100528A (zh) | 2021-01-01 |
CN113453762A (zh) | 2021-09-28 |
EA202191966A1 (ru) | 2021-12-08 |
CN113453762B (zh) | 2024-06-07 |
AU2020232044A1 (en) | 2021-09-02 |
KR20210135224A (ko) | 2021-11-12 |
IL285511B2 (en) | 2024-10-01 |
EP3936190A1 (en) | 2022-01-12 |
SG11202108780PA (en) | 2021-09-29 |
BR112021015975A2 (pt) | 2021-10-05 |
IL285511A (en) | 2021-09-30 |
JOP20210219A1 (ar) | 2023-01-30 |
IL285511B1 (en) | 2024-06-01 |
MA55221A (fr) | 2022-01-12 |
CL2021002144A1 (es) | 2022-02-04 |
TWI821537B (zh) | 2023-11-11 |
WO2020179780A1 (ja) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015131148A (ru) | СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ | |
AR112788A1 (es) | Compuesto pentacíclico | |
JP2016504363A5 (es) | ||
Moss | Nomenclature of fused and bridged fused ring systems (IUPAC Recommendations 1998) | |
NZ601128A (en) | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | |
JP2013519707A5 (es) | ||
JP2020522570A5 (es) | ||
IL273268A (en) | Process for the preparation of 7-(7,4-diazespiro[2.5]octan-7-yl)-2-(8,2-dimethylimidazo[2,1-B]pyridazin-6-yl)pyrido[2,1-A] pyrimidine-4-one | |
ZA200708524B (en) | Process for preparing pyrido[2,3-D]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one derivatives | |
NZ590688A (en) | imidazo[4,5-b]pyridin-2-one derivatives | |
HK1095818A1 (en) | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine-a2a-receptor antagonists | |
NZ623922A (en) | Novel tricyclic compounds | |
IL220174A0 (en) | 5-AMINO - {PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE}-2-AND 7-SUBSTITUTED DERIVATIVES AS ADENOSINE A2A RECEPTOR INHIBITORS | |
CA2434299A1 (en) | Tricyclic androgen receptor modulator compounds and methods | |
AP2528A (en) | Methods for the preparation of (3R,3aS,6aR) hexahydro- furo [2,3-b] furan-3-ol | |
AR118235A1 (es) | Heterociclos pentacíclicos | |
DE60202147D1 (de) | Imidazo(1,5-a!pyrimido)5,4-d!benz azepinderivate als gaba-a-rezeptormodulatoren | |
CA2474823A1 (en) | Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | |
JP2008542376A5 (es) | ||
TWI800696B (zh) | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 | |
WO2013042035A4 (en) | Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections | |
RU2004135086A (ru) | Гетероциклил-6-алкилиденпенемы в качестве ингибиторов бета-лактамазы | |
CA2477516A1 (en) | Pharmaceutical formulation comprising melatonin | |
JP2005533018A5 (es) | ||
RU2021123936A (ru) | Пентациклическое гетероциклическое соединение |